Stock Rating Downgrade
The Value Trend Rating for Theravance Biopharma Inc (NASDAQ: TBPH) weakened of late from C to D reflecting eroding fundamentals and low Appreciation Potential. Details supporting this lower rating are included in our next report.
Recent Price Action
Theravance Biopharma Inc (NASDAQ: TBPH) stock rose modestly by 0.9% on 2/28/25. The stock closed at $9.35. Moreover, trading volume in this advance was exceptionally high at 569% of normal. The stock has been strong relative to the market over the last nine months but has declined -3.2% during the last week.
Current PriceTarget Research Rating
Theravance Biopharma has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects inconsistent signals from PTR's two proprietary measures of a stock's attractiveness. Theravance Biopharma has a poor Appreciation Score of 18 but a neutral Power Rating of 58, producing the Negative Value Trend Rating.